Osteoporosis is a medical condition in which new calcium deposits in bone tissue cannot keep up with old bone calcium removal ...

Implementing opportunistic computed tomography (CT) bone density screening could increase the osteoporosis screening rate, yielding a reduction in medical costs.

The global osteoporosis drugs market size was valued at USD 14.90 billion in 2024 and is projected to reach USD 15.39 billion ...

Should you take a calcium supplement? And if so, how much? Here's what to know about calcium's benefits and some warnings.

To put it another way, women over the age of 45 will spend more days in hospital due to osteoporosis than they will for ...

A new study published in the journal of BMC Gasteroenterology found that patients with the liver cirrhosis had higher risk of ...

The "Osteoporosis_Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Osteoporosis Clinical ...

Romosozumab vs bisphosphonate use was not linked to increased CVD risks among patients with osteoporosis, challenging past concerns over its cardiovascular safety.

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD in postmenopausal women with T2D.